Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs

Gutierrez-Ardila M.V.; Reyes J.; Madariaga H.; Otero W.; Guzman R.; Izquierdo J.; Abello M.; Velez P.; Castillo D.; Ponce de Leon D.; Lukic T.; Amador L. · Expert Review of Pharmacoeconomics and Outcomes Research (2022) · DOI: 10.1080/14737167.2022.2047935

Resumen

Objective: To evaluate work productivity of adult Latin American patients with rheumatoid arthritis (RA) treated with tofacitinib and biological disease-modifying anti-rheumatic drugs (bDMARDs) measured by the Work Productivity and Activity Impairment (WPAI) in RA questionnaire at 0- and 6-month follow-up. Methods: This non-interventional study was performed in Colombia and Peru. Evaluated the effects of tofacitinib and bDMARDs in patients with RA after failure of conventional DMARDs. The WPAI-RA questionnaire was administered at baseline and at the 6-month (±1 month) follow-up. The results are expressed as least squares means (LSMs), and standard errors (SEs). Results: One hundred patients treated with tofacitinib and 70 patients treated with bDMARDs were recruited. Twenty-eight percent of patients from the tofacitinib group and 40.0% from the bDMARDs group were working for pay at baseline. At month 6, the changes in absenteeism, presenteeism, and work impairment due to health were −18.3% (SE 7.7), −34.8% (SE 5.9), and −11.0% (SE 16.5), respectively, in the tofacitinib group and −19.4% (SE 8.0), −34.8% (SE 6.2), and −15.9% (SE 15.0), for the bDMARD group. Conclusion: For patients who reported working, there were improvements in presenteeism, absenteeism, and work impairment due to health in both groups. Trial registration: NCT03073109.